

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/682,706
		Filing Date	10/09/2001
		First Named Inventor	Hsu et al.
		Group Art Unit	1646
		Examiner Name	Unassigned- Ruixiang Li
Sheet	1	of	2
Attorney Docket Number		STAN210	

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

RECEIVED
 JAN 16 2002
 TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ²	Number ²	Kind Code ³ (if known)				

+

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city, and/or country where published</small>		T ²
RLi	C1	Shibahara, S. et al. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene, The EMBO Journal (Vol.2 No.5 pp.775-779, 1983)		
	C2	Donaldson, CJ et al. Cloning and Characterization of Human Urocortin, Endocrinology (137:2167-2170, 1996)		
	C3	Chen, R. et al. Expression cloning of a human corticotropin-releasing-factor receptor, (Proc. Natl. Acad. Sci. USA, Vol.90, pp.8967-8971, October 1993)		
	C4	Liaw, C.W. et al. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid, (Dept. of Molecular Neurobiology, Neurocrine Biosciences, Inc., San Diego, CA;GENBANK/U34587, PMID:8536644, PubMed-indexed for MEDLINE)		



RL: ↓	C5	Grammatopoulos, D.K. et al. A Novel Spliced Variant of the Type 1 Corticotropin-Releasing Hormone Receptor with a Deletion in the Seventh Transmembrane Domain Present in the Human Pregnant Term Myometrium and Placental Membranes, (Molecular Endocrinology, Vol.13 No.12, The Endocrine Society, pp.2189-2202, 1999)	
	C6	Smith, G.W. et al. Corticotropin Releasing Factor Receptor 1-Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development, (Cell Press, Neuron, Vol.20, 1093-1102, June, 1998)	
	C7	Bale, T.L. et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress, (Nature Genetics, Letter, Vol.24, pp. 410-414, April 2000)	
↓	C8	Coste, S.C. et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2, (Nature Genetics, Letter, Vol.24, pp. 403-409, April 2000)	

Examiner Signature	<i>Ruimang L.</i>	Date Considered	4/7/2002
-----------------------	-------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 16 2002
TECH CENTER 1600/2900